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Abstract
Introduction Hyperglycaemia occurs frequently in the critically
ill, affects outcome adversely, and is exacerbated by enteral
feeding. Furthermore, treatment with insulin in this group is
frequently complicated by hypoglycaemia. In healthy patients
and those with type 2 diabetes, exogenous glucagon-like
peptide-1 (GLP-1) decreases blood glucose by suppressing
glucagon, stimulating insulin and slowing gastric emptying.
Because the former effects are glucose-dependent, the use of
GLP-1 is not associated with hypoglycaemia. The objective of
this study was to establish if exogenous GLP-1 attenuates the
glycaemic response to enteral nutrition in patients with critical
illness induced hyperglycaemia.
Methods Seven mechanically ventilated critically ill patients, not
previously known to have diabetes, received two intravenous
infusions of GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin)
over 270 minutes. Infusions were administered on consecutive
days in a randomised, double-blind fashion. On both days a
mixed nutrient liquid was infused, via a post-pyloric feeding
catheter, at a rate of 1.5 kcal/min between 30 and 270 minutes.
Blood glucose and plasma GLP-1, insulin and glucagon
concentrations were measured.
Results In all patients, exogenous GLP-1 infusion reduced the
overall glycaemic response during enteral nutrient stimulation
(AUC30–270 min GLP-1 (2077 ± 144 mmol/l min) vs placebo
(2568 ± 208 mmol/l min); P  = 0.02) and the peak blood
glucose (GLP-1 (10.1 ± 0.7 mmol/l) vs placebo (12.7 ± 1.0
mmol/l); P < 0.01). The insulin/glucose ratio at 270 minutes was
increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo
(5.8 ± 1.8); P = 0.02) but there was no difference in absolute
insulin concentrations. There was a transient, non-sustained,
reduction in plasma glucagon concentrations during GLP-1
infusion (t = 30 minutes GLP-1 (90 ± 12 pmol/ml) vs. placebo
(104 ± 10 pmol/ml); P < 0.01).
Conclusions Acute, exogenous GLP-1 infusion markedly
attenuates the glycaemic response to enteral nutrition in the
critically ill. These observations suggest that GLP-1 and/or its
analogues have the potential to manage hyperglycaemia in the
critically ill.
Trial Registration Australian New Zealand Clinical Trials
Registry number: ACTRN12609000093280.
Introduction
Hyperglycaemia occurs frequently, even in patients without
pre-existing diabetes [1], and adversely affects outcome [2].
For this reason, treatment with insulin is widely used; however,
insulin therapy is associated with a substantial risk of hypogly-
caemia, which is associated with both short- and long-term
adverse events [3,4]. Although the use of parenteral nutrition
affords a stable caloric load, which minimises the incidence of
hypoglycaemia [2], enteral feeding is the preferred method of
nutrient delivery in critically ill patients [5]. Hence, there is a
AUC: area under the curve; CV: coefficient of variation; ELISA: enzyme linked immunosorbent assay; GLP-1: glucagon-like peptide-1; NS: not signif-
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need for a therapy to manage hyperglycaemia in enterally fed
patients without the risk of hypoglycaemia [6].
Exogenous administration of the incretin hormone, glucagon-
like peptide-1 (GLP-1), has been shown to normalise blood
glucose concentrations both in healthy patients and those with
type 2 diabetes [7]. This occurs as a result of stimulation of
insulin secretion, suppression of glucagon release and slow-
ing of gastric emptying [7,8]. Because the former effects are
glucose dependent, the use of GLP-1 does not appear to be
associated with hypoglycaemia [9]. The effect of GLP-1 on
glycaemia in enterally fed critically ill patients has hitherto not
been evaluated. The primary aim of this study was to determine
whether exogenous GLP-1 attenuates the glycaemic
response to small intestinal nutrient infusion in critically ill
patients not previously known to be diabetic.
Materials and methods
Subjects
Seven critically ill adult patients (four males, three females, age
range 28 to 76 years), predicted to remain mechanically venti-
lated for more than 48 hours, were studied. Exclusion criteria
included pregnancy, pre-existing diabetes, contraindication to
enteral feeding or post-pyloric catheter insertion, and previous
surgery on the oesophagus, stomach or duodenum.
The study was approved by the Human Ethics Committee of
the Royal Adelaide Hospital and performed according to the
Australian National Health and Medical Research Committee
guidelines for the conduct of research involving unconscious
persons. Written, informed consent was obtained from the
next of kin.
Study protocol
Patients were studied on two consecutive days, in which they
received intravenous GLP-1 or placebo in a randomised, dou-
ble-blind fashion. Twelve hours prior to the study, a naso-duo-
denal feeding catheter was inserted and confirmed via
abdominal x-ray. On each study day enteral feeding was
ceased at least four hours prior to the commencement of the
study. Exogenous insulin (Actrapid, Novo-Nordisk, Copenha-
gen, Denmark) infusion was ceased at least two hours before
the commencement of the study drug. Patient weight was pro-
vided by a relative and/or estimated by a dietician. Randomisa-
tion and reconstitution of synthetic GLP-1-(7–36) amide
(Merck Biosciences, Melbourne, Australia), as a solution in 4%
albumin, was performed by the Royal Adelaide Hospital Phar-
macy department. The study investigators were blinded to
each infusion, which were concealed in a glass bottle covered
by black plastic. Both GLP-1 (1.2 pmol/kg/min) and placebo
(4% albumin) were infused at a rate of 1 ml/min via a central
venous catheter for 270 minutes (i.e. t = 0 to 270 min). At t =
30 minute Ensure® (Abbott, Melbourne, Australia), a mixed
nutrient liquid (64% carbohydrate, 1 kcal/ml), was delivered
continuously into the small intestine at a rate of 1.5 ml/min for
four hours (i.e. t = 30 to 270 min). An arterial blood sample
was obtained every 15 minutes for measurement of blood glu-
cose and at timed intervals for measurements of plasma insu-
lin, GLP-1 and glucagon concentrations.
Data analysis
Blood glucose was measured at the bedside using a portable
glucometer (Medisense Optimum, Abbott, Melbourne, Aus-
tralia). Blood was collected, separated by centrifugation and
the resulting plasma was stored at -70° until assayed for hor-
mone concentrations. Plasma insulin was measured by ELISA
(Diagnostics Systems Laboratories, Webster, Texas, USA)
with an inter-assay coefficient of variation (CV) of 6.2%. Total
plasma GLP-1 (GLPIT-36HK Linco Research, St. Charles,
Missouri, USA) and glucagon (Siemens Medical Solution
Diagnostics, Berkeley, California, USA) concentrations were
measured by radioimmunoassay, with a CV of 9.2% and 12%,
respectively.
Statistical analysis
Data are presented as mean ± standard error of the mean.
Area under the curve (AUC) was calculated using the trapezoi-
dal rule. The number of patients required to establish a glu-
cose lowering effect of GLP-1 was based on power
calculations derived from our previous work [8]. The ratios of
insulin/glucose were calculated, as described previously [10].
Statistical analyses were performed using SPSS (Version
15.0, Chicago, Illinois, USA). Distribution and sensitivity anal-
ysis, using nonparametric analyses, allowed parametric testing
of data. The difference between intervention and placebo was
assessed using paired samples; Student's paired t-test and
repeated measures analysis of variance. Data were evaluated
for potential carry over effect. The null hypothesis was rejected
at the 0.05 significance.
Results
The study was well tolerated in all patients. Patient details are
shown in Table 1.
Blood glucose
Blood glucose concentrations are shown in Figure 1. There
was no difference in baseline blood glucose concentration
prior to each infusion (t = 0 min GLP-1 7.5 ± 0.4 mmol/l vs.
placebo 7.6 ± 0.6 mmol/l; P = not significant (NS)). Prior to
the commencement of the small intestinal nutrient infusion (t =
30 min) GLP-1 had no effect on blood glucose. On both days,
there was an increase in blood glucose concentration in
response to intra-duodenal nutrient infusion (t = 180 min GLP-
1 9.3 ± 0.6 mmol/l; placebo 12.2 ± 0.9 mmol/l; P < 0.01 for
both). GLP-1 markedly attenuated the rise in blood glucose
(e.g. t = 60 min GLP-1 7.5 ± -0.5 mmol vs. placebo 9.5 ± -0.8
mmol; P  < 0.01), peak blood glucose (GLP-1 10.1 ± 0.7
mmol/l vs. placebo 12.7 ± 1.0 mmol/l; P  < 0.01) and
decreased the overall glycaemic response (AUC30–270 minAvailable online http://ccforum.com/content/13/3/R67
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GLP-1 2077 ± 144 mmol/l min vs. placebo 2568 ± 208
mmol/l min; P = 0.02).
Plasma insulin
Plasma insulin and insulin:glucose ratio is shown in Figures 2a
and 2b. There was no difference in plasma insulin concentra-
tion at baseline. Plasma insulin increased in response to intra-
duodenal nutrient (e.g. t = 270 min GLP-1 79 ± 21 mU/l and
placebo 61 ± 17 mU/l; P < 0.03 compared with fasting con-
centration for both days). At 270 minutes, the insulin/glucose
ratio was greater with GLP-1 (GLP-1 9.1 ± 2.7 vs. placebo 5.8
± 1.8; P = 0.02); however, there was no difference in absolute
plasma insulin concentrations throughout the entire study
period (AUC0–270 min GLP-1 16,203 ± 5193 mU/l min vs. pla-
cebo 14,434 ± 4561 mU/l min; P = NS).
Plasma GLP-1
Plasma GLP-1 concentrations are shown in Figure 2c. Fasting
plasma GLP-1 concentrations were similar between groups (t
= 0 min GLP-1 36 ± 10 pmol/l vs. placebo 38 ± 11 pmol/l; P
= NS). Exogenous GLP-1 markedly increased plasma GLP-1
concentration within 30 minutes (t = 30 min GLP-1 124 ± 15
pmol/l vs. placebo 43 ± 9 pmol/l; P < 0.01) and throughout
the infusion period (AUC0–270 min GLP-1 31,659 ± 4203 pmol/
l min) vs. placebo 10,399 ± 2508 pmol/l min; P < 0.01). Dur-
ing GLP-1 infusion, steady state concentrations were
achieved after 30 minutes (t = 30 min plasma GLP-1 124 ±
15 pmol/l vs. t = 90 min plasma GLP-1 131 ± 13 pmol/l; P =
NS).
Plasma glucagon
Plasma glucagon concentrations are shown in Figure 2d. Fast-
ing glucagon concentrations were similar between study days
(t = 0 min GLP-1 106 ± 14 pmol/ml vs. placebo 102 ± 13
pmol/ml; P = NS). There was a decrease in plasma glucagon
from baseline during GLP-1 infusion (t = 30 min GLP-1 90 ±
12 pmol/ml vs. placebo 104 ± 10 pmol/ml; P < 0.01), which
was non-sustained (AUC0–270 minutes GLP-1 22,786 ± 6040
pmol/l min vs. placebo 25,830 ± 2644 pmol/l min); P = NS).
Table 1
Summary demographic data of patients studied
Age Mean 58 years
Sex 4 male:3 female
Diagnosis 4 medical:3 surgical
APACHE II (admission) Mean 18
APACHE II (study) Mean 17
Days in intensive care unit Mean 7 days
Serum creatinine (μmol/l) Mean 73 μmol
Plasma albumin(g/l) Mean 23 g/l
Feed tolerant1 5 of 6 tolerant of EN
Inotropes 1 patient on catecholamine infusion
Parenteral nutrition 0 of 7
Weight Mean 84 kgs
Rate of insulin infusion when ceased2 Mean 2.0 U/hour
Total insulin dose in previous 24 hours Mean 57 U/24 hours
All data refer to results from the first study day unless otherwise specified.
1 Patients are feed-tolerant if (over the preceding 24 hours): delivery of nutrient liquid is at the target rate (as determined by on-site dietician) and 
gastric residual volumes less were than 250 mL in any six-hour period.
2 The infusion rate at t = -120 minutes (i.e. when exogenous insulin ceased).
APACHE = Acute Physiology and Chronic Health Evaluation.
Figure 1
Exogenous glucagon-like peptide-1 (GLP-1) attenuated the rise in  blood glucose levels and the overall glycaemic response to intra-duo- denal nutrient infusion Exogenous glucagon-like peptide-1 (GLP-1) attenuated the rise in 
blood glucose levels and the overall glycaemic response to intra-duo-
denal nutrient infusion. (AUC30–270 min GLP-1 2077 ± 144 mmol/l min 
vs. placebo 2568 ± 208 mmol/l min; P = 0.02). Data are mean ± SEM 
(n = 7). * P < 0.05.Critical Care    Vol 13 No 3    Deane et al.
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Discussion
This is the first study to evaluate the effect of exogenous GLP-
1 infusion on the glycaemic response to enteral nutrition dur-
ing critical illness. Given the need to avoid hyperglycaemia and
hypoglycaemia in critically ill patients, an assessment of the
effect of exogenous GLP-1 is of considerable interest.
The dose of GLP-1 used in the current study was based on a
previous study in which infusion of GLP-1 at 1.2 pmol/kg/min
achieved fasting normoglycaemia, and was well tolerated in
postoperative patients with type 2 diabetes [11]. Hyperglycae-
mia in critically ill patients, not previously known to have diabe-
tes, is associated with poorer outcomes than in patients with
pre-existing diabetes [12]. Hence, we chose to study the
effect of exogenous GLP-1 in these patients. Insulin infusions
were ceased two hours before the commencement of the
study to ensure clearance of exogenous insulin. Given the
short plasma half life of GLP-1 [13] carry over effects were not
anticipated or observed, and a crossover protocol was an
appropriate study design. The nutrient type and load were
selected on a feeding regimen which aims to deliver 25 kcal/
kg/day of mixed nutrient liquid [14]. Accordingly, 1.5 kcal/min
of Ensure® was administered. Hyperglycaemia in critical ill-
ness is believed to reflect inadequate insulin secretion, hepatic
and peripheral insulin resistance, and an increase in the coun-
ter-regulatory hormones cortisol, catecholamines, glucagon
and growth hormone [15]. Only plasma insulin and glucagon
concentrations were measured, as GLP-1 is not known to alter
the secretion of the other counter-regulatory hormones and
the study was designed to establish proof of concept [9].
Exogenous GLP-1 slows gastric emptying substantially [8]
and this may be the dominant mechanism by which GLP-1
reduces postprandial glycaemic excursions [16]. Hence, the
magnitude of glucose lowering by GLP-1 is likely to be even
greater during gastric, rather than small intestinal, nutrient
administration [17]. However, delayed gastric emptying
occurs in approximately 50% of critically ill patients and, when
marked, may lead to under-nutrition, gastro-oesophageal reflux
and pulmonary aspiration [18]. Given the above considera-
tions it was appropriate to initially determine whether GLP-1
attenuates the glycaemic response to small intestinal, rather
than intra-gastric, nutrient. Whether GLP-1 will slow gastric
emptying further in critically ill patients remains to be deter-
mined.
It should be recognised that nutrient-induced hyperglycaemia
was only attenuated, and not suppressed completely by GLP-
1. This may potentially reflect an insufficient GLP-1 dose, and
larger doses are known to be well tolerated [19]. As dis-
cussed, given the effect of GLP-1, to slow gastric emptying, it
is possible that the magnitude of glucose lowering will be
greater during gastric feeding. However, some critically ill
patients may also have inadequate β-cell reserve to compen-
sate for the disordered hormone milieu even at larger doses
and/or during gastric feeding. Given the complexity and sever-
ity of disordered glucose metabolism in the critically ill, and an
ongoing requirement for nutrition, it is anticipated that exoge-
nous GLP-1 may achieve normoglycaemia only in specific sub-
groups of patients. However, this study establishes the con-
cept that GLP-1 as sole therapy, or in combination with insulin,
has the potential to manage hyperglycaemia in the critically ill.
We elected to evaluate the effects of an acute GLP-1 infusion
in a relatively small, heterogeneous cohort of critically ill
patients studied at various times after their admission. This lim-
itation should be recognised and may have been of greater rel-
evance if the study outcome had been negative, rather than
positive. Although our study only measured the effect of a
Figure 2
Plasma Hormone concentrations Plasma Hormone concentrations. There was no increase in total post-
prandial insulin secretion (a), however the plasma insulin/blood glu-
cose ratio was increased at t = 270 minutes (b). Exogenous glucagon-
like peptide-1 (GLP-1) infusion increased plasma GLP-1 concentra-
tions (c) and caused a transient, but non-sustained, suppression of glu-
cagon (d). Data are mean ± SEM (n = 7). * P < 0.05.Available online http://ccforum.com/content/13/3/R67
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short-term infusion, it is likely that the glucose-lowering effect
would persist for the entire period of GLP-1 administration
[20]. Furthermore, we speculate that longer-term GLP-1 infu-
sion may result in less glycaemic variability than the current
approach to insulin therapy, because of its effects on both
insulin and glucagon. An additional limitation is the inconclu-
sive evidence regarding insulin stimulation and glucagon sup-
pression. Although there were no observed differences in
absolute insulin concentrations during the entire GLP-1 infu-
sion, there was an increase in the insulin/glucose ratio and
transient suppression of glucagon secretion. Moreover, the
number of subjects included was based on power calculations
for a glucose-lowering effect and the study may have been
underpowered to establish effects on insulin and glucagon
over the entire study period. Given the positive outcome of this
study, additional studies are required to further elucidate the
mechanisms underlying the effects of GLP-1 and determine
the optimal dose and duration of treatment in the critically ill.
Conclusions
This study establishes that exogenous GLP-1 infusion limits
the peak blood glucose, and markedly attenuates the overall
glycaemic response, during small intestinal feeding, in non-
diabetic critically ill patients. Given exogenous GLP-1 may
improve the safety and efficacy of glycaemic control in this
group, further investigation into its potential use is warranted.
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